04 Mar
2021
14:59 E.S.T.

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results

Read more

25 Feb
2021
15:29 E.S.T.

Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST

Read more

16 Feb
2021
01:00 E.S.T.

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells

Read more

15 Dec
2020
19:18 E.S.T.

Cellectis Announces Withdrawal of Follow-On Offering

Read more

14 Dec
2020
15:48 E.S.T.

Cellectis Announces Launch of Follow-On Offering

Read more

05 Dec
2020
17:00 E.S.T.

Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting

Read more

17 Nov
2020
18:58 E.S.T.

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma

Read more

16 Nov
2020
16:30 E.S.T.

Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

Read more

05 Nov
2020
16:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020

Read more

04 Nov
2020
00:00 E.S.T.

American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALL

Read more